Browse studies

Find your next paid study

740 recruiting studies matching your filters

Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)

This phase II trial tests the effect of botensilimab and balstilimab before surgery (neoadjuvant) in treating patients with high-risk clear cell renal cell can…

Clear Cell Renal Cell CarcinomaStage II Renal Cell Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07516366

Phase 3

Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian …

Advanced Ovarian CarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Tumor+22 more

Estimated

Observational

A Pilot Study Using Hyperthermic Irrigation Followed by Intravesical Chemotherapy in Patients With Low- to Intermediate-Risk Non-Muscle Invasive Bladder Cancer

The goal of this prospective pilot study is to evaluate the safety and feasibility of using heated saline during bladder tumor surgery in patients with non-mus…

Bladder CancerBladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)Non-muscle Invasive Bladder Cancer (NMIBC)+6 more

Estimated

~$10 – $6,250

CAMC Health SystemNCT07817173

Data Collection of Standard Care of Patients in the EMG Section

Background: Most people who are referred to the EMG (Electromyography) Section of the NIH are enrolled into specific active studies. This allows researchers t…

NeuropathyMuscle DisordersDysautonomia

Estimated

~$10 – $675

National Institute of Neurological Disorders and Stroke (NINDS)NCT05041387

Phase 2

ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 p…

Non-muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma

Estimated

~$10 – $7,500

John SfakianosNCT06503614

Observational

Effects of Resistance Exercise Among TGD Individuals Initiating Estrogen-Based Gender-Affirming Hormone Therapy

Estrogen-dominant gender-affirming hormone therapy (GAHT) is standard of care for transgender women and gender-diverse individuals and typically consists of es…

Muscle Mass and Strength

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT07400419

Phase 3

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-1)

The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous …

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)

Estimated

~$10 – $8,750

EMD Serono Research & Development Institute, Inc.NCT07332481

Role of Genetic Factors in the Pathogenesis of Lung Disease

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examini…

Cystic FibrosisPulmonary FibrosisTuberous Sclerosis+2 more

Estimated

~$10 – $675

National Heart, Lung, and Blood Institute (NHLBI)NCT00001532

Phase 3

A Phase 3, Multicenter, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children a…

Multiple Sclerosis, Relapsing-Remitting

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06408259

Observational

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study

Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the …

ALS - Amyotrophic Lateral Sclerosis

Estimated

~$10 – $8,750

PathMaker Neurosystems Inc.NCT06649955

Phase 1

A Phase 1 Study Evaluating the Safety and Preliminary Efficacy of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic CAR T Cell Product in Autoimmune Disease

This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune dise…

Systemic Lupus Erythematosus (With and Without Nephritis)Idiopathic Inflammatory MyopathySystemic Sclerosis

Estimated

~$10 – $8,750

Allogene TherapeuticsNCT07085104

Phase 1

Phase 1/2 Investigation of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (Pioneer-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002

PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects…

Amyotrophic Lateral Sclerosis

Estimated

~$10 – $8,750

Vector Y TherapeuticsNCT07287397